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OBJECTIVE: The objective of this systematic EBM review is to determine “Does dupilumab 
decrease the amount of asthma exacerbations in patients suffering from asthma compared to 
placebo?” 
 
STUDY DESIGN: A review of three randomized, placebo-controlled trials (RCTs) that were 
peer reviewed and published in English after 2009.   
 
DATA SOURCE: All articles were published in peer reviewed journals and were researched 
using PubMed. Studies were selected based on their ability to answer the question posed in the 
objective, and if the researched outcomes were patient oriented.    
 
OUTCOMES: Assessed outcomes were either the occurrence or rate of asthma exacerbations 
during the studies. The specifics of a defined exacerbation were similar, but minimally different 
between each randomized controlled trial. Exacerbations according to the authors are as follows:  
i. Wenzel (2013): “>1 systemic glucocorticoid burst, in patient hospitalization, or an 
emergency department visit for worsening asthma” 
ii. Wenzel (2016): “deterioration of asthma that required the use of systemic 
corticosteroids for at least 3 days, or hospital admission or emergency department 
visit because of asthma treated with systemic corticosteroids” 
iii. Rabe: “events leading to hospitalization, and ED visit, or treatment of >3days with 
systemic glucocorticoids at >2 times the current”  
 
RESULTS: All three studies found that Dupilumab had a large treatment effect on patients with 
asthma and decreased exacerbations. Wenzel et al. (2013) found a NNT of three, with an odds 
ratio (OR) of 0.08 (95% CI, 0.02 to 0.28, p<0.001) in favor of intervention decreasing risk for 
exacerbation. Wenzel et al. (2016) had a NNT of seven, with a risk reduction percentage of 
70.5% (95% CI, 45.4-84.1%, pvalue=0.0001) with Dupilumab intervention. And Rabe et al. 
found an RR of 0.407 (95% CI, 0.263 to 0.630) meaning there is less than half the risk of an 
exacerbation with intervention.  
 
CONCLUSIONS: The results of these three studies showed that Dupilumab does decrease the 
amount of asthma exacerbations compared to placebo in patients suffering from asthma. 
However, further research with more patients needs to be conducted with more consistent 
treatment protocols to understand optimal dosing.  
 
KEYWORDS: Dupilumab, asthma 
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INTRODUCTION: 
Asthma is a chronic disease with genetic predisposition that is characterized by varying 
levels of airway obstruction, inflammation and hyperresponsiveness. Symptoms can be both 
episodic or chronic, but are considered to be reversible either spontaneously or post-
bronchodilator therapy as reported by an increase of >12% in FEV1.1 The reversibility of 
obstruction using a bronchodilator is what separates asthma from other obstructive lung diseases 
such as chronic bronchitis or emphysema. Patients with persistent, moderate-severe asthma who 
are uncontrolled may be having daily symptoms of wheezing, coughing and dyspnea despite 
treatment with inhaled corticosteroids (ICS), long acting beta agonists (LABA) and rescue 
inhalers putting them at a greater risk for exacerbations and hospital admission.1,2  
Asthma is a common chronic disease amongst all age groups that effects healthcare 
providers in many different settings. The incidence of asthma accounts for 24.6 million 
Americans3, and more than 250 million people affected worldwide.2 Asthma patients account for 
8-10% of the population1, and 20-25% of those diagnosed are considered to have moderate to 
severe uncontrolled disease. Uncontrolled asthma, meaning that a patient still experiences 
symptoms and exacerbations despite the use of maintenance medications such as ICS and some 
other controller or systemic corticosteroids.2  
With the increasing prevalence of asthma over the past 20 years, there is both a large 
economic and resource burden placed on healthcare systems worldwide. In the United States 
alone, there are some 10 million hospital visits and 1.8 million emergency room visits each year 
as a result of asthma. These emergency room visits ultimately result in more than 3,500 deaths in 
the US, most commonly amongst young blacks between the ages of 15 and 24.1 As a result, in 
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2013 about $50.3 billion was spent in the US on medical costs for asthma alone, not including 
the $29 billion from asthma-related mortality.4  
Usual treatment methods depend largely on the severity and frequency of a patient’s 
symptoms and are often approached with a stepwise treatment plan. This includes starting with a 
short acting beta agonist such as albuterol for quick relief in addition to a maintenance ICS of 
varying dosages such as budesonide or fluticasone for those with persistent asthma. LABAs such 
as salmeterol are often added on for patients already on ICS with poor control, in addition to 
other adjunct medications such as leukotriene receptor antagonists montelukast or zafirlukast.1 
Biologic medications are being explored further as adjuncts for the treatment of uncontrolled 
asthma. Omalizumab has been found to be helpful in patients with a positive skin test due to its 
effect on the inhibition of IgE binding which has a key role in allergic asthma symptoms.1,2 
Other biologics such as reslizumab and mepolizumab affect interleukin5, and have been found 
effective in patients with elevated eosinophilic asthma. With poor asthma control, patients are 
placed at a greater risk of a life-threatening exacerbation and a decreased quality of life. 
Symptoms of breathlessness, inability to complete full sentences and a sensation of chest 
tightness are common complaints during an asthma exacerbation. Exacerbations are treated with 
a combination of supplemental oxygen, inhaled SABA via nebulizer or metered dose inhaler 
(MDI) treatment, and oral systemic corticosteroids contributing to immunosuppression. 
The mechanisms associated with poor asthma control in those who are using ICS and 
LABAs is not fully understood.3 More recent research has come to find that about half of 
patients with asthma have inflammatory cytokines attributed to type 2/Th2 inflammation, and 
new therapies are being tested to reduce this specifically to improve control.2  
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Dupilumab (Dupixent®) has shown success and improvement with other type 2 
inflammatory disease processes such as atopic dermatitis and chronic sinusitis, common 
comorbidities of asthma.2 This information is making researchers hopeful that Dupilumab, a 
fully human monoclonal antibody, will be helpful in asthma control therapy through the 
inhibition of interleukins-4 and 13 involved in Th2 inflammatory pathways.2 Dupilumab may be 
used as an add-on controller medication to decrease the amount of severe exacerbations 
experienced by asthma patients, especially those with moderate to severe asthma. This paper 
evaluates three randomized placebo-controlled trials comparing the efficacy and safety of anti-
interleuken-4 receptor monoclonal antibody Dupilumab in the treatment of persistent asthma and 
its prevention of asthma exacerbations. 
OBJECTIVE:  
The objective of this systematic EBM review is to determine “Does Dupilumab decrease 
the amount of asthma exacerbations in patients suffering from asthma compared to placebo?” 
METHODS:  
Resources and scholarly literature were selected by the author of this paper based on their 
ability to answer the question: Does Dupilumab decrease the amount of asthma exacerbations in 
patients suffering from asthma compared to placebo? The articles were also selected because 
they discuss a new intervention being proposed for better asthma control that includes a patient 
oriented outcome (POEM), in this case decreased occurrence of an exacerbation. All articles 
were published in peer-reviewed journals in English, with exclusion criteria including articles 
that were published before 2009. All three of the studies included are double-blind, randomized, 
placebo-controlled clinical trials published in years 2013, 2016 and 2018 found using the key 
words “Dupilumab” and “asthma” through the resource database Pubmed. Inclusion criteria 
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Table 1. Demographics and Characteristics of Included Studies  
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included studies that were randomized controlled trails, and those published within the past 10 
years. Statistics reported and used include OR, RR, NNT and p-values. 
The selected studies, as detailed above in Table 1, include a population of patients 
diagnosed with asthma, who were given the intervention of 300mg Dupilumab, at either weekly 
or every two week frequencies depending on the study. Changes to patients’ previous asthma 
control medications throughout each study slightly varied. The patients that were given the 
intervention were all compared to an experimental group who received a similar appearing 
placebo and the measured outcome was the occurrence or rate of asthma exacerbations. 
OUTCOMES:  
Outcomes were measured by the occurrence of a severe exacerbation in both Wenzel 
studies, and as a rate of severe asthma exacerbations in Rabe 2018 study. The definitions of an 
exacerbation were similar, but minimally different between studies.  
I. Wenzel (2013): “>1 systemic glucocorticoid burst, in patient hospitalization, or an 
emergency department visit for worsening asthma”.3 
II. Wenzel (2016): “deterioration of asthma that required the use of systemic 
corticosteroids for at least 3 days, or hospital admission or emergency department 
visit because of asthma treated with systemic corticosteroids”.2  
III. Rabe: “events leading to hospitalization, and ED visit, or treatment of >3days with 
systemic glucocorticoids at >2 times the current”.5  
RESULTS:  
Wenzel et al. (2013) study was a randomized placebo-controlled trial that took place in 
28 different sites throughout the US. Patients were required to have an elevated eosinophil count 
(>300 cells/µL) in addition to diagnosis of moderate to severe asthma not properly controlled 
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with medium to high dose ICS and a LABA inhaler before the start of the trial. All patients were 
between the ages of 18 and 65, with uncontrolled symptoms. A ratio of 1:1 was used to 
randomize via a “centralized system” to achieve randomization allocation concealment.3 Patients 
in the intervention group were given 300mg Dupilumab or placebo every week. Unique to this 
study, patients were required to taper their maintenance medications such that they discontinued 
their LABA at week four, and then continued to taper their ICS so that they would discontinue 
by weeks six through nine of the total 12-week intervention period. This particular study looked 
at the occurrence of an asthma exacerbation during the 12-week intervention as their primary 
outcome, and patients continued to receive the study drug all 12 weeks or until they had an 
exacerbation. Of those receiving Dupilumab, 6% had an exacerbation compared to 44% in the 
placebo group (Table 2).3 The study reports an OR far below one, at 0.08 (95% CI, 0.02 to 0.28; 
p<0.001) with Dupilumab, indicating that the intervention decreased the risk for asthma 
exacerbation in this study in patients that were given the intervention compared to placebo.3 
Given dichotomous data from the researchers, a NNT of 3 was calculated indicating that for 
every three moderate to severe persistent asthmatics treated with Dupilumab, one more asthma 
exacerbation will be prevented compared to the placebo. A low NNT and an OR significantly 
smaller than one with a narrow CI, indicates a large treatment effect that is statistically 
significant based on the reported p-value. It is important to note that although more than 20% of 
the placebo group discontinued the study, it was due to a “lack of efficacy”, considering that the 
patients had to discontinue their LABA and ICS. This means that patients were possibly 
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Table 2. Occurrence of Asthma Exacerbation in Wenzel et al. 2013 Study 
Intervention Occurrence of asthma exacerbation during 12 wk 
intervention 
Dupilumab (n=52) 3 (6%) 
Placebo (n=52) 23 (44%)  
 
Wenzel et al. 2016 is a randomized placebo-controlled clinical trial that took place in 174 
sites across 16 different countries. Patients in this 2016 trial had similar inclusion criteria such as 
being >18 years old, with an asthma diagnosis for >12 months and those uncontrolled on 
medium to high-dose ICS and a LABA inhaler. The main difference in patient population in this 
study was that patients were selected irrespective of their blood eosinophil counts, including 
those with greater than and less than 300 cells/µL.2 Results were reported for both the overall 
population, and in the different subgroups based on eosinophil count. Reference exclusion 
criteria in Table 1. With a total of 769 patients, there were four different intervention groups with 
150-157 patients each, and a placebo group with 158. Randomization was achieved via a 
centralized allocation system. Different interventions included receiving Dupilumab 
subcutaneous (SQ) 200mg every two or four weeks, and 300mg every two or four weeks.2 All 
intervention groups received a loading dose double that of their normal dose for the first 
injection. More than 89% of patients completed the study (689/769 total patients).2  
For this review, results regarding the 300mg SQ injection every two weeks were utilized 
for calculation purposes and conclusions in this report. Amongst patients who received this 
intervention, a statistically significant risk reduction percentage of 70.5% (95% CI, 45.4-84.1%, 
p value=0.0001) was found when compared to placebo. Of those receiving Dupilumab 300mg 
every two weeks, 11% suffered from an exacerbation compared to 26% in the placebo 
intervention.2 Because this information was reported as dichotomous data within the study, NNT 
of 7 was calculated indicating another large treatment effect. For every seven adults with 
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uncontrolled persistent asthma treated with Dupilumab 300mg every two weeks, one more 
person will have an asthma exacerbation prevented compared to placebo.  
Table 3. Calculations for NNT in Both Wenzel et al. Studies 
Study EER CER RRR ARR NNT 
Wenzel 2013 0.94 0.56 0.67 0.38 3 
Wenzel 2016 0.89 0.74 0.20 0.15 7 
 
The final study, by Rabe et al., was a randomized, placebo-controlled international study 
that included 210 patients. Inclusion criteria in this study was slightly different and included 
patients >12 years old, with an asthma diagnosis > 12 months with oral glucocorticoid dependent 
severe asthma who were receiving systemic steroids within the six months preceding the study in 
addition to a high dose ICS and up to two other inhalers. Review Table 1 for exclusion criteria. 
Researchers allowed a three to 10 week adjustment period for the patient’s oral glucocorticoids 
before beginning the 24 week intervention. Patients were either given 300mg SQ Dupilumab 
with an initial loading dose of 600mg every two weeks, or matched placebo. Oral steroid doses 
were reduced and adjusted during weeks four through 20.5 Randomization to receive placebo or 
intervention was achieved via a “voice web response technology.”5  
The rate of a severe exacerbation was recorded by the researchers, but this could not be 
converted to dichotomous data for a NNT calculation. The study did however find a relative risk 
versus placebo of 0.407 (95% CI, 0.263 to 0.630) meaning that there is less than half the risk of 
an exacerbation with 300mg Dupilumab every two weeks compared to placebo.5 There is no 
reported p-value. Although the treatment effect is also large, the existence of a wider confidence 
interval makes the data found less precise, meaning that results in other studies may show 
dissimilar results. However, there is not large concern that the intervention would increase the 
risk of these patients’ exacerbations given that the CI does not exceed one. Loss of subjects who 
did not complete the entire intervention was less than 20%. 
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 Among all three studies, the most common adverse event included an injection site 
reaction and erythema, with other common events such as upper respiratory tract infection or 
headache. Treatment was tolerable for patients in all studies. Notable to mention, in the study 
done by Wenzel et al. 2016, there were two patient deaths, although they were in the intervention 
group with Dupilumab 300mg every four weeks, not every two weeks. According to the authors, 
the deaths were unrelated to treatment as one patient passed from acute heart failure and the 
other from metastatic gastric cancer with complications of pneumonia and cor pulmonale.2 No 
deaths were recorded in either of the two other studies.  
Table 4. Most Common Adverse Events in All Studies 







Dupilumab (n=52) 15 (29%) 7 (13%) 6 (12%) 
Placebo (n=52) 5 (10%) 9 (17%) 3 (6%) 
Wenzel 
2016 
Dupilumab (n=156)  33 (21%) 20 (13%) 17 (11%) 
Placebo (n=158) 12 (8%) 28 (18%) 20 (13%) 
Rabe 
2018  
Dupilumab (n=103) 9 (9%) 9 (9%) Not reported  
Placebo (n=107) 4 (4%) 19 (18%) Not reported  
 
DISCUSSION: 
 Previous clinical trials researching antibody treatment options for Th2 inflammatory 
diseases have shown consistent positive results in patients with elevated eosinophil counts, 
explaining why Wenzel et al. 2013 initially only included patients with blood eosinophil counts 
>300 cells/µL.3 Interestingly enough, future studies including the other two analyzed in this 
review have found that Dupilumab was successful in decreasing exacerbation risk and improving 
lung function in asthma patients regardless of their baseline blood eosinophil count.2,5  
 There are other labeled uses for Dupilumab including moderate to severe atopic 
dermatitis and chronic rhinosinusitis with nasal polyposis that were successful before using it in 
trials as an adjunct asthma medication. Similar to when treating asthma, some of the most 
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common adverse reactions found were injection site reactions.6 In studies specifically involving 
patients with atopic dermatitis, severe eye irritation in addition to blepharitis, conjunctivitis and 
keratitis were recorded as adverse effects not reported in asthma trials.7 The only 
contraindication for Dupilumab found is a known hypersensitivity to the drug or any of its 
components and there are currently no black box warnings.6,7 However, Dupilumab is known to 
have drug interactions with live vaccines and simultaneous injections should thus be avoided if 
possible. Patients who are using Dupilumab for atopic dermatitis are advised to continue taking 
their asthma medications as directed unless otherwise advised by their healthcare provider to 
prevent unnecessary exacerbations.6 Due to the successful treatment of several comorbid 
conditions, it is possible that this one drug will be able to treat all conditions systemically at 
once.2  
 Research on this topic was limited in the author’s search given that only PubMed was 
used to find studies that answered the question: “Does Dupilumab decrease the amount of asthma 
exacerbations in patients suffering from asthma compared to placebo?”. It is possible that there 
are more, and better studies to be found on other databases. Limitations of the studies themselves 
include relatively small sample size and short duration of treatment. In addition to that, the 
methodology of each study was slightly different in how they altered their patients’ previous 
medications making direct comparison more difficult. For example, in Wenzel et al. 2013 study, 
patients were changing their maintenance medication at weeks four, six, and nine giving them 
little time to adjust to each dose3. In the Rabe et al. study, the only medication that changed was 
their oral corticosteroids, but these patients maintained their inhalers throughout the whole 
study5. In addition to this, none of the studies included a “worst-case” analysis on patients lost to 
follow-up. Both Wetzel et al. studies excluded missed data from their analysis, and Rabe et al. 
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used a mixed model. It would increase validity to find risk reductions and a low NNT despite the 
fact that all patients who left the study were counted towards exacerbation rates or counts in their 
respective studies. A final limitation notable to mention found in the study by Rabe et al., is that 
because the annualized rate of severe exacerbations reported was not the primary endpoint of 
their study, it was not “controlled for comparison” and thus only reported a confidence interval, 
but no p-value for complete statistical significance.5  
CONCLUSION:  
 According to the results reported in this systemic review, Dupilumab does decrease the 
amount of asthma exacerbations in patients diagnosed with asthma compared to placebo. 
Statistically significant, large treatment effects were found in both studies published by Wetzel et 
al. with small NNT of 3 and 7, and a significant risk reduction percentage with Dupilumab at 
95% confidence in study by Rabe et al. Further research however needs to be done to confirm the 
most ideal dose and administration schedule given that there were differences in that regard 
amongst studies. Future research would be most beneficial if they included larger sample sizes, 
and monitored treatment effects and adverse events for a longer period of time for increased 
confidence in Dupilumab treatment of uncontrolled asthma. Data analysis could also be 
incorporated to look at patients specifically with comorbid asthma and atopic dermatitis or 
chronic sinusitis to monitor improvement of all conditions at the same time to see if there is 
increased effect on one condition over another. And finally, patient population may also be 
expanded to include children six and older, as use is approved in this age group for the treatment 
of severe atopic dermatitis.6 Although other current ongoing studies with Dupilumab were not 
found in my research, new treatment options for patients with uncontrolled asthma will continue 
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